FDA Chastises Novartis Unit Over Safety Issues

Law360, New York (January 30, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration has sent a warning letter to the vaccine-making subsidiary of Novartis AG over a number of “significant deviations” from quality-control practices at one of the Swiss drugmaker's facilities in Germany.

The letter, sent Jan. 24 to Novartis Vaccines and Diagnostics Chief Executive Joerg Reinhardt and made public on the FDA's Web site on Tuesday, said that during an inspection of the Marburg, Germany-based plant last September, investigators had “documented a number of significant deviations from current good manufacturing practices" in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.